Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Part B/Part D Drug Coverage Shifts Should Await 2008, CMS Tells Congress

Executive Summary

The Centers for Medicare & Medicaid Services believes switching drug coverage for a small number of products from Part B to Part D is worth considering, but not until the outpatient drug benefit has been underway for at least two years

You may also be interested in...



Biologics Under Part D: Coinsurance, Cost Containment And Coverage Overlap

Coinsurance appears to be the preferred cost-sharing method for biologics in Medicare Part D plans, according to an analysis of plan formularies by "The Pink Sheet."

Biologics Under Part D: Coinsurance, Cost Containment And Coverage Overlap

Coinsurance appears to be the preferred cost-sharing method for biologics in Medicare Part D plans, according to an analysis of plan formularies by "The Pink Sheet."

Medicare Rx Requires Pharmacies To Mind Their B’s And D’s

Pharmacists will have to keep careful track of prescriptions for some medicines that can be covered by Medicare Part B once the new Part D outpatient drug benefit begins in 2006

Topics

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel